Lu-177 Psma I&t

Lutetium (177Lu) Zadavotide Guraxetan is a radiopharmaceutical used for targeted therapy. It is designed for intravenous use and is manufactured by Curium Finland Oy.

Lutetium (177Lu) Zadavotide Guraxetan is primarily used in targeted radionuclide therapy. This radiopharmaceutical is designed to deliver radiation directly to specific cells, aiming to minimize damage to surrounding healthy tissue. It is often explored in contexts where targeted treatment is beneficial, such as certain types of cancer.

Lutetium (177Lu) Zadavotide Guraxetan works by emitting radiation that can affect the targeted cells. Patients may experience various effects, which can vary widely depending on individual factors. Common effects might include fatigue or localized reactions at the injection site.

Handling Lutetium (177Lu) Zadavotide Guraxetan requires careful precautions due to its radioactive nature. It should only be administered by trained healthcare professionals in a controlled environment. Proper shielding and safety measures are essential to protect both the patient and the healthcare provider.

Lutetium (177Lu) Zadavotide Guraxetan may interact with other medications or treatments, particularly those that affect the bone marrow or immune system. It is important to disclose all current medications and treatments to the healthcare provider before administration. Additionally, interactions with other radioactive substances should be carefully considered.